JPRN-UMIN000005328招募中2 期
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer. - A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.
Dept. of Respiratory Medicine, Osaka University Hospital0 个研究点目标入组 45 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with at least one of the following conditions are ineligible 1)Have central nervous system metastases 2) Radiological evidence of tumor invading or abutting major blood vessels and evidence of brain metastases, even if previously treated. But eligible for disappeared or controlled brain metastases 3)history of active double cancer within 5 years 4)History of hemoptysis with 2.5mL or more. a) continue hemosputum for more than one week b) have had or require continuous oral administration of hemostat c) have had or require injectable administration of hemostat 5)Have possibly complication related to bleeding episode 6)Great vessel involvement 7)Have received radiation therapy to lesions of lung 8)Currently have or have a history of a cardiac effusion which requires treatment 9)Currently have brain vascular disease with symptom, or have a history of it within one year before enrollment 10)Have a serious concomitant active infection, which needs antibiotics, antimycotic drugs or virucide 11)Operation has been scheduled for the treatment period 12)Receiving anticoagulant drug(including Aspirin over 325mg/day). 13)Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year. 14)Uncontrollable Hypertension or Gastrointestinal ulceration 15)Severe cardiac disease 16)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 17)Peripheral neuropathy > Grade2 18)Hypersensitivity of Protocol agents or Taxans or alcohol and the medicine made of the polio castor oil content. 19)Cases with past history of administration of Protocol agents 20) Pregnancy, breast feeding and suspected pregnancy 21) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004651-23-FRInstitut Jules Bordet180
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209
招募中
2 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer2024-511850-34-00Institut Jules Bordet209
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
已完成
2 期
A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancerJPRN-UMIN000001358West Japan Oncology Group40